Mehros Wala, Aldosari Sarah, Alharbi Rahaf, Alshareef Wasan, Hawsawi Wesal, Fallata Halah, Aljifree Hatim, Althubaiti Alaa
Department of Oncology King Abdul-Aziz Medical City, Ministry of The National Guard Health Affairs, Jeddah, Saudi Arabia.
King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Front Oncol. 2025 Sep 5;15:1594233. doi: 10.3389/fonc.2025.1594233. eCollection 2025.
Uterine carcinosarcoma is a rare, aggressive biphasic tumor comprising both carcinomatous and sarcomatous elements. The overall prognosis of women with uterine carcinosarcoma is poor, with a median overall survival of less than two years. The predictors of survival for patients with uterine carcinosarcoma in the Kingdom of Saudi Arabia have not yet been fully elucidated; this study therefore explored the demographic features and prognostic factors of uterine carcinosarcoma.
This A cross-sectional study was conducted among all confirmed carcinosarcoma cases at Princess Noorah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia, from January 2003 to December 2023. Data were collected on demographic features, medical history, stage, treatment modality, and disease outcome.
A total of 34 patients with carcinosarcoma were identified, accounting for 4.7% of all endometrial cancer cases. Sixty percent of patients were diagnosed early, during stages 2B and below. The most common presentation was post-menopausal bleeding, occurring in 90% of the sample. Kaplan-Meir analysis revealed an overall median survival of 14 months.
The findings confirmed the aggressiveness of the tumor. Late tumor stage was identified as a factor affecting patients' survival and outcome, being associated with poor prognosis and short survival time.
子宫癌肉瘤是一种罕见的侵袭性双相肿瘤,由癌性和肉瘤性成分组成。子宫癌肉瘤女性患者的总体预后较差,中位总生存期不到两年。沙特阿拉伯王国子宫癌肉瘤患者的生存预测因素尚未完全阐明;因此,本研究探讨了子宫癌肉瘤的人口统计学特征和预后因素。
本横断面研究对2003年1月至2023年12月在沙特阿拉伯吉达国民警卫队医院努拉公主肿瘤中心确诊的所有癌肉瘤病例进行。收集了有关人口统计学特征、病史、分期、治疗方式和疾病结局的数据。
共确定了34例癌肉瘤患者,占所有子宫内膜癌病例的4.7%。60%的患者在2B期及以下被早期诊断。最常见的表现是绝经后出血,在90%的样本中出现。Kaplan-Meir分析显示总体中位生存期为14个月。
研究结果证实了该肿瘤的侵袭性。肿瘤晚期被确定为影响患者生存和结局的一个因素,与预后不良和生存期短相关。